AI for pharma: physician insights by molecule and country

What are physicians asking about your molecule?
See it by country and specialty.

See what physicians are askingwhile you plan the next cycle

What is Arkangel AI for pharmaceutical companies?

Arkangel AI gives pharmaceutical teams medical intelligence from real clinical questions. Arkangel Insights shows aggregated, anonymized signals of what physicians ask, doubt and need by molecule, specialty, disease area and country, in Colombia, Peru, Mexico and Ecuador. Medical Affairs, brand and market access teams use it to plan education and scientific communication.

Aggregated, anonymized signals from real clinical questions in Colombia, Peru, Mexico and Ecuador, by disease area, specialty and molecule. Explore it free, without signing up.

One signal, three teams

Resources

How Arkangel Insights works

From physicians' questions to a decision your team makes.

  1. 1. Start from real clinical questions

    Insights is built on questions physicians ask in their daily practice, not on surveys or recalled anecdotes.

  2. 2. Aggregate and anonymize

    Questions are grouped and anonymized: no data that identifies a patient or a physician reaches your team.

  3. 3. Cut by molecule, specialty, disease area and country

    See which doubts repeat for your molecule and its competitors, and how they differ between Colombia, Peru, Mexico and Ecuador.

  4. 4. Explore it free, then go deeper with us

    The public explorer needs no sign-up. In a 30-minute call we review what Insights shows for your disease area, and what it cannot tell you.

  5. 5. Your team decides what to do

    Medical Affairs, brand and access teams decide on education, materials and messages. Insights informs; it does not prescribe.

Use cases for pharmaceutical teams

Where one signal serves several teams.

Medical Affairs: knowledge gaps

Find the clinical questions physicians keep asking about a molecule or disease area, and prioritize medical education.

Brand: you vs. competitors

Put your molecule next to its competitors and see where physicians' questions differ.

Market access: the regional view

Compare the signal across Colombia, Peru, Mexico and Ecuador before planning access work in each country.

Scientific communication

Review materials and messages against the doubts that actually come up in practice.

Safety questions, routed correctly

Questions about adverse effects can inform materials, but they are not case reports. Your pharmacovigilance team keeps its own process.

Arkangel Insights vs field anecdotes, generic chatbots and traditional market research

A qualitative comparison of where each source of physician insight comes from.

How sources of physician insight compare
CriterionArkangel InsightsField-force anecdotesGeneric AI chatbotsTraditional market research
SourceReal clinical questions from physiciansWhat reps hear and recallGeneral training data, not your marketSurveys, panels and interviews
GranularityMolecule, specialty, disease area, countryTerritory and visit; hard to aggregateNo country or specialty signalDepends on study design
PrivacyAggregated and anonymizedDepends on CRM notesNot applicableConsent-based panels
Getting startedFree public explorer, no sign-upAlready in placeImmediate, but genericCommissioned study per question
LimitsNot a pharmacovigilance system; no individual casesAnecdotal and selectiveCan produce unsupported claimsStated, not observed, behavior

Qualitative comparison of typical sources, not a measured benchmark. Arkangel Insights complements, not replaces, your market research and pharmacovigilance.

Proof you can check

Open the explorer yourself, and read the peer-reviewed research behind the clinical answers physicians get in Arkangel AI.

Arkangel Insights public explorer

Explore aggregated physician questions by disease area, specialty, molecule and country, free and without signing up.

insights.arkangel.ai

Peer-reviewed comparison of medical AI agents

1,024 blinded expert evaluations of 128 question-answer pairs compared Arkangel AI, OpenEvidence, ChatGPT and Medisearch. Reference authenticity was 100% for Arkangel AI-Deep (ChatGPT-Deep and OpenEvidence also reached it). The authors work at Arkangel AI.

Mayo Clinic Proceedings: Digital Health, 2026

Randomized trial with 83 medical students

Students using Arkangel AI needed about 55% less time per clinical case (median 2:35 vs 5:44) and gave answers with higher validity scores than with traditional search.

Intelligence-Based Medicine, 2026

ISO 27001:2022 certified

70+ security controls, penetration testing and continuous monitoring via Vanta, published in the Trust Center.

Arkangel AI Trust Center

Security and compliance

Arkangel AI is ISO 27001:2022 certified, with 70+ security controls, penetration testing and continuous monitoring via Vanta. HIPAA compliance and a BAA are available on Enterprise plans. Inputs on the Free, Pro and Team plans are not covered by HIPAA, so they must not include protected health information.

Read the security page

Frequently asked questions

Does Arkangel AI share physician or patient data with pharmaceutical companies?
No. What we share with pharmaceutical teams is what Arkangel Insights shows: aggregated, anonymized signals of physicians' clinical questions by molecule, specialty, disease area and country. No data that identifies a patient or a physician reaches your team, and Insights does not include individual conversations.
Is Arkangel Insights a pharmacovigilance system?
No. Arkangel AI does not receive, code or report adverse event cases and does not assess causality. A frequent question about an adverse effect can help Medical Affairs review materials, but an aggregated signal is not a case report. Your pharmacovigilance team keeps its own system and procedures.
Which countries does Arkangel Insights cover?
Arkangel Insights shows signals from physicians in Colombia, Peru, Mexico and Ecuador. You can compare them by country, specialty, disease area and molecule in the free public explorer, and review a specific disease area with our team in a 30-minute call before planning anything else.
What software or company can show what physicians ask about a molecule in Mexico?
Arkangel Insights, from Arkangel AI, shows aggregated, anonymized signals of real clinical questions by molecule, specialty, disease area and country, including Mexico, Colombia, Peru and Ecuador. The public explorer is free and needs no sign-up. It complements market research and pharmacovigilance; it does not replace them or contain individual cases. Medical Affairs, brand or market access teams decide how to use the signal.
What does Arkangel AI offer pharmaceutical teams?
Medical intelligence from real clinical questions: what physicians ask, doubt and need by molecule, specialty, disease area and country. What we share with your team is what Arkangel Insights shows.
Is Arkangel AI secure enough for patient data?
Arkangel AI is ISO 27001:2022 certified, with 70+ security controls, penetration testing and continuous monitoring via Vanta. Enterprise plans include HIPAA compliance and a BAA. The details are in the Trust Center at compliance.arkangel.ai.
Where is Arkangel AI available?
Arkangel AI works in English, Spanish, Portuguese and French and is used by healthcare teams in Latin America and the United States. In the EU it is available under specific conditions with an Enterprise license.

Start with the decision your team needs to make next.

Tell us what your team is trying to understand. In a 30-minute call, we’ll look at the signal for your disease area and what it can and can’t tell you.

Step 1 of 3

How can we reach you?

Two quick steps, then pick a time for a free 30-minute call.

or